Maximizing Efficiency in
Your Laboratory Workflow
For Autoimmune, Infectious Disease, and Specialty Testing
-
BioPlex 2200 System for MMRV Testing
The BioPlex 2200 System provides two panels for the qualitative determination of IgG and IgM serological status to measles (rubeola), mumps, rubella (IgG only), and varicella (VZV) to meet evolving clinical needs.
From the detection of active infections with the BioPlex 2200 MMV IgM panel to the assessment of serological status for vaccine-preventable diseases with the BioPlex 2200 MMRV IgG panel, these solutions provide a streamlined assessment of serological status for all your laboratory needs.
Harness the Power of Multiplexing with the BioPlex 2200 MMRV IgG and MMV IgM Panels
The BioPlex 2200 System uses multiplex technology to generate multiple results within a single test, eliminating the need for multiple assay runs or separate reflex testing when performing complex testing algorithms. This powerful capability improves result throughput and turnaround time.
Testing for Vaccine-Preventable Diseases
Measles, mumps, rubella, and varicella (VZV) are highly contagious diseases that can rapidly spread through susceptible populations causing outbreaks. These diseases are preventable by vaccinations4 and understanding a person’s immune status helps identify whether vaccinations or boosters should be administered. Early identification of infected individuals is important to expedite treatments and minimize the spread of these diseases.
The BioPlex 2200 MMRV IgG panel streamlines the testing of these vaccine-preventable diseases. Pre-pregnancy or prenatal MMRV IgG testing determines the immune status of the woman and allows clinicians to determine if vaccinations are needed. Pre-employment screening with MMRV IgG is useful for testing those in healthcare, military, or other high-risk positions, to prevent the infection and spread of vaccine-preventable diseases.
The BioPlex 2200 MMV IgM panel provides streamlined testing for active MMV infections. When immune status (IgG) alone is insufficient, it can also be used to detect suspected acute infections.
The BioPlex 2200 System also offers a diverse infectious disease menu that includes tests for TORCH, HIV, and syphilis, among others.
-
Watch Our Labroots Webinar
Role of Serology for Congenital Infections and Vaccine-Preventable Diseases in the Prenatal Setting
In this educational webinar, our speakers provide an overview of congenital infections and the use of serological testing in detecting and preventing prenatal infections.
-
Guest Speakers
Alan Wu, PhD
Chief of Clinical Chemistry
and Toxicology Laboratories,
San Francisco General Hospital
Russell Neuner, PhD
Research and Development Manager, Clinical Immunology,
Bio-Rad Laboratories
“Negative MMRV IgG results may also be an indication of waning immunity in previously vaccinated individuals or the absence of prior vaccination.”
-
The Role of Serologic Testing in the Assessment of Immunity to Measles, Mumps, Rubella, and Varicella1
Melanie L. Yarbrough, PhD, D(ABMM)
Download Whitepaper
Department of Pathology and Immunology
Washington University School of Medicine
Saint Louis, Missouri, USA 
-
Confidence in Results
- Integrated QC beads verify assay performance and ensure result integrity in every test
- Ready-to-use kits, calibrators, and controls minimize reagent handling errors
- Excellent assay precision for reliable and consistent results
- Agreement with CDC Rubella IgG-specific panel and correlated to WHO Rubella IgG standard
BioPlex 2200 MMRV IgG Performance
A clinical study revealed that the BioPlex 2200 MMRV IgG Panel demonstrated excellent performance when screening for MMRV IgG across different cohorts, including prenatal and pre-employment.2
| BioPlex 2200 MMRV IgG |
Performance * | |||
|---|---|---|---|---|
| Negative % Agreement | Positive % Agreement | |||
| Pregnant Women (N=396) |
Pre-Employment Screening (N=393) |
Tests Ordered (N=790) |
||
| Measles (Rubeola) | 100% | 97.6% | 99.7% | 98.2% |
| Mumps | 100% | 99.7% | 100% | 95.8% |
| Rubella | 97.6% | 99.5% | 98.9% | 97.6% |
| VZV | 100% | 98.9% | 97.8% | 96.1% |
* Excludes equivocal results. All assays are qualitative and performance is relative against corresponding commercially available assays.
BioPlex 2200 MMV IgM Performance
The BioPlex 2200 MMV IgM Panel demonstrated excellent performance in a clinical study when testing for antibodies against MMV IgM.3
| BioPlex 2200 MMV IgM |
Performance * | |||||
|---|---|---|---|---|---|---|
| Positive % Agreement | Negative % Agreement | |||||
| Healthy Donors (N=300) |
Tests Ordered (N=300) |
|||||
| Measles (Rubeola) | 96.0% | 100% | 99.3% | |||
| Mumps | 96.6% | 97.9% | 96.9% | |||
| VZV | 98.8% | 100% | 97.9% | |||
* Excludes equivocal results. All assays are qualitative and performance is relative against corresponding commercially available assays.
Efficiency of Multiplex Testing
-
- Determine serological status or active infection
for vaccine-preventable diseases with two tests - Consolidate test methods on a fully automated,
random-access multiplex platform to eliminate
manual and batch testing - Reduce laboratory waste and optimize reagent
storage - Improve turnaround time by decreasing send-out
testing
- Determine serological status or active infection
More Results, Less Effort.
Do More with Less
Easily generate multiple results from a single test panel
Improve Workflow Efficiency
Simplify laboratory workflow by consolidating individual tests into multiplexed panels
Report Results Confidently
High-quality results with full automation and assay performance verification in every test
BioPlex 2200 System
BioPlex 2200 MMRV IgG Panel
For simultaneous detection and differentiation of IgG antibodies to:
- Measles (Rubeola)
- Mumps (German Measles)
- Rubella
- VZV (Varicella Zoster)
BioPlex 2200 MMV IgM Panel
For simultaneous detection and differentiation of IgM antibodies to:
- Measles (Rubeola)
- Mumps (German Measles)
- VZV (Varicella Zoster)
References
- Yarbrough ML (2018). The Role of Serologic Testing in the Assessment of Immunity to Measles, Mumps, Rubella and Varicella. Washington Univ School of Medicine and Bio-Rad White Paper, T-299.
- BioPlex 2200 MMRV IgG IFU
- BioPlex 2200 MMV IgM IFU
- ProQuad MMRV IFU
-
BioPlex 2200 MMRV IgG Testing
The BioPlex 2200 MMRV IgG assay uses multiplex technology to streamline the assessment of vaccine-preventable diseases by generating up to four individual results in a single test.
Harness the Power of Multiplexing with the BioPlex 2200 MMRV IgG Panel
One Test. Multiple Results.
The BioPlex 2200 System uses multiplex technology to generate multiple results within a single test, eliminating the need for multiple assay runs or separate reflex testing when performing complex testing algorithms. This powerful capability improves result throughput and turnaround time.
MMRV IgG Testing for Vaccine-Preventable Diseases
Measles, mumps, rubella, and varicella (VZV) are highly contagious diseases that are preventable by vaccinations.3 Understanding a person’s immune status helps identify whether vaccinations or boosters should be administered.
-
The BioPlex 2200 MMRV IgG panel streamlines the testing of these vaccine-preventable diseases. Pre-pregnancy or prenatal MMRV IgG testing determines the immune status of the woman and allows clinicians to determine if vaccinations are needed. Pre-employment screening with MMRV IgG is useful for testing those in healthcare, military, or other high-risk positions, to prevent the infection and spread of vaccine-preventable diseases.
The BioPlex 2200 System also offers a diverse infectious disease menu that includes tests for TORCH, HIV, and syphilis, among others.
-
Watch Our Labroots Webinar
Role of Serology for Congenital Infections and Vaccine-Preventable Diseases in the Prenatal Setting
In this educational webinar, our speakers provide an overview of congenital infections and the use of serological testing in detecting and preventing prenatal infections.
-
Guest Speakers
Alan Wu, PhD
Chief of Clinical Chemistry
and Toxicology Laboratories,
San Francisco General Hospital
Russell Neuner, PhD
Research and Development Manager, Clinical Immunology,
Bio-Rad Laboratories
“Negative MMRV IgG results may also be an indication of waning immunity in previously vaccinated individuals or the absence of prior vaccination.”
-
The Role of Serologic Testing in the Assessment of Immunity to Measles, Mumps, Rubella, and Varicella1
Melanie L. Yarbrough, PhD, D(ABMM)
Download Whitepaper
Department of Pathology and Immunology
Washington University School of Medicine
Saint Louis, Missouri, USA
-
Confidence in Results
- Integrated QC beads verify assay performance and ensure result integrity in every test
- Ready-to-use kits, calibrators, and controls minimize reagent handling errors
- Excellent assay precision for reliable and consistent results
- Agreement with CDC Rubella IgG-specific panel and correlated to WHO Rubella IgG standard
BioPlex 2200 MMRV IgG Performance
A clinical study revealed that the BioPlex 2200 MMRV IgG Panel demonstrated excellent performance when screening for MMRV IgG across different cohorts, including prenatal and tests ordered.2
| Bioplex 2200 MMRV IgG |
Performance | ||
|---|---|---|---|
| Negative % Agreement | Positive % Agreement | ||
| Pregnant Women (N=396) |
Tests Ordered (N=1183) |
||
| Measles (Rubeola) | 100% | 93.3% | 94.7% |
| Mumps | 100% | 94.3% | 90.4% |
| Rubella | 95.9% | 97.9% | 94.8% |
| VZV | 100% | 95.1% | 94.0% |
All assays are qualitative and performance is relative against corresponding commercially available assays.
Efficiency of Multiplex Testing
-
- Determine serological status for up to four
vaccine-preventable diseases with a single test - Consolidate test methods on a fully automated,
random-access multiplex platform to eliminate
manual and batch testing - Reduce laboratory waste and optimize reagent
storage - Improve turnaround time by decreasing send-out
testing
- Determine serological status for up to four
More Results, Less Effort.
Do More with Less
Easily generate multiple results from a single test panel
Improve Workflow Efficiency
Simplify laboratory workflow by consolidating individual tests into multiplexed panels
Report Results Confidently
High-quality results with full automation and assay performance verification in every test
BioPlex 2200 System
BioPlex 2200 MMRV IgG Panel
For simultaneous detection and differentiation of IgG antibodies to:
- Measles (Rubeola)
- Mumps (German Measles)
- Rubella
- VZV (Varicella Zoster)
References
- Yarbrough ML (2018). The Role of Serologic Testing in the Assessment of Immunity to Measles, Mumps, Rubella and Varicella. Washington Univ School of Medicine and Bio-Rad White Paper, T-299.
- BioPlex 2200 MMRV IgG IFU
- ProQuad MMRV IFU
Disclaimer
* These pages list our product offerings in these areas. Some products have limited regional availability. If you have a specific question about
products available in your area, please contact your local sales office or representative.